
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
Jeff Stark, MD, is vice president and head of medical immunology, UCB. He is also a rheumatologist by training and leads UCB’s medical affairs team across the key focus areas of dermatology and rheumatology.
Published: February 6th 2025 | Updated:
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.